Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
Human Endogenous Metabolite
|
---|---|
ln Vitro |
DU-145 prostate cancer cells are susceptible to dose-dependent inhibitory activity from 4,5-Dicaffeoylquinic acid (0.1~100 µM; 72 h), which also induces cell cycle arrest and Bcl-2 inactivation[2].
When administered at concentrations of 10 to 100 µg/mL, 4,5-Dicaffeoylquinic acid (1~100 µg/mL; 48 h) significantly increases cell viability in D-GalN-challenged HL-7702 hepatocytes by preventing apoptosis.The maximum inhibition rates of 4,5-Dicaffeoylquinic acid (1~100 µg/mL; 4 days) on the expressions of HBsAg and HBeAg are 86.93 and 59.79%, respectively. This is a significant inhibition of HBsAg and HBeAg expressions[3]. |
ln Vivo |
In type 2 diabetic mice, 4,5-Dicaffeoylquinic acid effectively reduces glycemia and insulin resistance and improves insulin sensitivity by increasing the expression of GLUT2, GK, and PDX-1 protein[1].
|
Cell Assay |
Cell Line: HL-7702 hepatocytes (exposure to 80 mM D-GalN for 6h)
Concentration: 1~100 μg/mL Incubation Time: 48 h Result: produced a maximum protection rate of 47.28% at 100 µg/mL and greatly increased cell viability at concentrations of 10 to 100 µg/mL. |
References |
|
Molecular Formula |
C25H24O12
|
---|---|
Molecular Weight |
516.4509
|
CAS # |
57378-72-0
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O
|
InChi Key |
UFCLZKMFXSILNL-RVXRWRFUSA-N
|
InChi Code |
InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(35,24(33)34)11-19(30)23(20)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,35H,11-12H2,(H,33,34)/b7-3+,8-4+/t19-,20-,23+,25-/m1/s1
|
Chemical Name |
(1R,3R,4S,5R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,5-dihydroxycyclohexane-1-carboxylic acid
|
Synonyms |
Isochlorogenic acid C
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~50 mg/mL (~96.81 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9363 mL | 9.6815 mL | 19.3630 mL | |
5 mM | 0.3873 mL | 1.9363 mL | 3.8726 mL | |
10 mM | 0.1936 mL | 0.9681 mL | 1.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Histopathologic examination of pancreas in diabetic mice (HE stain, × 400). [1].Nutr Metab (Lond). 2018 Oct 10;15:73. td> |
Insulin immunohistochemistry of pancreas in diabetic mice (× 400).[1].Nutr Metab (Lond). 2018 Oct 10;15:73. td> |
Effect of GD on GLUT2, GK, MafA, PDX-1, Bcl-2, Bax, and caspase-3 protein expressions in pancreatic tissues. [1].Nutr Metab (Lond). 2018 Oct 10;15:73. td> |